MedTrace Logo

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

NCT02606903 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2018-12-27

Study results available
· View outcomes & findings →

Summary

To investigate and compare the pharmacokinetics, safety and tolerability of BI 695501 administered subcutaneously via prefilled syringe or autoinjector

Conditions

  • Healthy

Interventions

DRUG

BI 695501 prefilled syringe

DRUG

BI 695501 autoinjector

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-28
Primary Completion
2016-09-07
Completion
2016-10-04

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02606903 on ClinicalTrials.gov